Acepodia (ROCO:6976) Capex-to-Operating-Income : 0.00 (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Acepodia Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Acepodia's Capital Expenditure for the six months ended in Jun. 2024 was NT$-69.47 Mil. Its Operating Income for the six months ended in Jun. 2024 was NT$-310.19 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Acepodia Capex-to-Operating-Income Historical Data

The historical data trend for Acepodia's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acepodia Capex-to-Operating-Income Chart

Acepodia Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Acepodia Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Capex-to-Operating-Income	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Acepodia's Capex-to-Operating-Income

For the Biotechnology subindustry, Acepodia's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acepodia's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acepodia's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Acepodia's Capex-to-Operating-Income falls into.

Acepodia Capex-to-Operating-Income Calculation

Acepodia's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-179.37)	/	-435.974
	=	N/A

Acepodia's Capex-to-Operating-Income for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-69.47)	/	-310.187
	=	N/A

Acepodia (ROCO:6976) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Acepodia Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Acepodia's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Acepodia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acepodia Inc (ROCO:6976) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

17th floor-12, Number 99, Section 1, Xintai 5th Road, Xizhi District, New Taipei, TWN, 22175

Website

https://www.acepodia.com

Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cell therapies by using Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.

Acepodia Headlines

No Headlines